Lessons from the TREAT trial:
Ticagrelor is as safe as clopidogrel for STEMI patients
treated with fibrinolysis
01 Sep 2018
Ischaemic heart disease was the principal cause of death in Malaysia in 2016, and ST-segment elevation myocardial infarction (STEMI) is noted as the deadliest clinical presentation of Acute Coronary Syndrome. At the National Heart Association of Malaysia’s 2018 Annual Scientific Meeting, Professor Dr Wan Azman Wan Ahmad shared his insights into the management of STEMI in Malaysia, highlighting the implications of the recent TREAT trial.
Related MIMS Drugs